Hematopoietic stem cell transplantation in advanced cutaneous T-cell lymphoma.

Abstract

We retrospectively reviewed data pertaining to five patients with cutaneous T-cell lymphoma (CTCL) who had received hematopoietic stem cell transplantation (HSCT) between 2004 and 2015 at Kurume University Hospital, along with their clinical data until March 2016. For patients with advanced CTCL eligible for HSCT, autologous HSCT was performed when they responded well to chemotherapy, and allogeneic HSCT was selected for patients with advanced mycosis fungoides (MF)/Sézary syndrome (SS) and CTCL other than MF/SS with poor chemosensitivity. Two patients (primary cutaneous anaplastic large cell lymphoma and primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma) who responded well to chemotherapy received autologous HSCT: one patient was alive in partial remission and the other died due to therapy-related acute myeloid leukemia without disease relapse. In the remaining three patients with MF or SS, allogeneic HSCT was performed. Although one patient with MF died due to disease progression, the remaining two patients were alive in complete remission. Although there were two deaths in this study, the outcomes were considered satisfactory.

• Authors: Hiroshi Saruta, Chika Ohata, Ikko Muto, Taichi Imamura, Eijiro Oku, Koichi Ohshima, Koji Nagafuji, Takekuni Nakama
• Journal: The Journal of dermatology (J Dermatol) Vol. 44 Issue 9 Pg. 1038-1042 (Sep 2017) ISSN: 1346-8138 [Electronic] England
• PMID: 28391645 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2017 Japanese Dermatological Association.

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Disease Progression
• Female
• Hematopoietic Stem Cell Transplantation
• Humans
• Male
• Middle Aged
• Mycosis Fungoides (pathology, therapy)
• Retrospective Studies
• Sezary Syndrome (pathology, therapy)
• Skin Neoplasms (pathology, therapy)
• Transplantation, Autologous
• Transplantation, Homologous